Tuesday, June 23, 2020, 5:00 PM – 6:30 PM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from PracticeA Complimentary CNE (NCPD) Live Webinar Series

Chimeric Antigen Receptor T-Cell Therapy

Register Today for This CNE (NCPD) Virtual Event — 1.5 Credit Hours Available

Live Webinar

Join Us on Tuesday, June 23
5:00 PM – 6:30 PM ET

Complimentary Registration
A link to the event will be provided after registration.


Faculty to be announced


Neil Love, MD
Research To Practice
Miami, Florida

Topics for Discussion

  • Module 1: Optimal Integration of CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy into the Management of Aggressive Lymphomas
  • Module 2: Current Role and Ongoing Investigation of CAR T-Cell Therapy in Acute Lymphoblastic Leukemia; Incidence, Severity and Management of Toxicities Related to CAR T-Cell Therapy
  • Module 3: Emerging Role of Anti-BCMA CAR T-Cell Therapy in the Management of Multiple Myeloma
A detailed agenda will be made available in the coming weeks.

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of hematologic cancers.

Learning Objectives and Goals
Upon completion of this activity, participants should be able to:

  • Develop an understanding of the biologic rationale for the development of chimeric antigen receptor (CAR) T-cell therapy as a targeted strategy to eliminate cancer cells, and appreciate the similarities and differences between commercially available and investigational products.
  • Appraise existing and emerging efficacy data from clinical trials of approved and investigational CAR T-cell therapies directed at CD19 for patients with relapsed/refractory B-cell lymphomas, and utilize this information to identify individuals who may be suitable candidates for this approach.
  • Understand how CAR T-cell therapies have been evaluated in patients with acute lymphoblastic leukemia and consider how approved CAR-T platforms may be appropriately integrated into the care of individuals with this disease.
  • Appreciate available data documenting the activity of CAR T-cell therapy directed against B-cell maturation antigen and utilize this knowledge to identify patients with multiple myeloma who may be appropriate for this therapeutic approach as part of a clinical trial.
  • Recognize adverse events and other common side effects associated with approved and investigational CAR T-cell therapies, and implement strategies to educate patients eligible for this treatment about the potential for these complications.
  • Recall the scientific rationale for and new data supporting the ongoing investigation of novel applications of CAR T-cell therapy, and counsel appropriately selected patients about study participation.
Accreditation Statement
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by RTP.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form, which will be emailed to attendees after the event.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by RTP or the ANCC. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures
RTP is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE (NCPD) activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

RTP CNE (NCPD) planning committee members, staff and reviewers — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from Celgene Corporation, Kite, A Gilead Company, and Novartis.